CA3136466A1 - Methods for the administration of certain vmat2 inhibitors - Google Patents

Methods for the administration of certain vmat2 inhibitors

Info

Publication number
CA3136466A1
CA3136466A1 CA3136466A CA3136466A CA3136466A1 CA 3136466 A1 CA3136466 A1 CA 3136466A1 CA 3136466 A CA3136466 A CA 3136466A CA 3136466 A CA3136466 A CA 3136466A CA 3136466 A1 CA3136466 A1 CA 3136466A1
Authority
CA
Canada
Prior art keywords
patient
inhibitor
parkinson
signs
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3136466A
Other languages
English (en)
French (fr)
Inventor
Dao Tuyet THAI-CUARTO
Barbara SCHOLZ
Grace S. LIANG
Eiry W. ROBERTS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of CA3136466A1 publication Critical patent/CA3136466A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3136466A 2019-05-09 2020-05-08 Methods for the administration of certain vmat2 inhibitors Pending CA3136466A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962845599P 2019-05-09 2019-05-09
US62/845,599 2019-05-09
PCT/US2020/032188 WO2020227672A1 (en) 2019-05-09 2020-05-08 Methods for the administration of certain vmat2 inhibitors

Publications (1)

Publication Number Publication Date
CA3136466A1 true CA3136466A1 (en) 2020-11-12

Family

ID=70919120

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3136466A Pending CA3136466A1 (en) 2019-05-09 2020-05-08 Methods for the administration of certain vmat2 inhibitors

Country Status (17)

Country Link
US (2) US20200397779A1 (https=)
EP (1) EP3965764A1 (https=)
JP (2) JP2022531696A (https=)
KR (1) KR20220007105A (https=)
CN (1) CN114340624A (https=)
AU (2) AU2020270145A1 (https=)
BR (1) BR112021020709A2 (https=)
CA (1) CA3136466A1 (https=)
EA (1) EA202193012A1 (https=)
IL (2) IL321020A (https=)
JO (1) JOP20210274A1 (https=)
MA (1) MA55893A (https=)
MX (1) MX2021013132A (https=)
PH (1) PH12021552745A1 (https=)
SG (1) SG11202111465RA (https=)
TW (1) TWI850377B (https=)
WO (1) WO2020227672A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3051830A1 (en) 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
MA53239A (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
CA3220946A1 (en) * 2021-06-30 2023-01-05 Angel S. Angelov Valbenazine for use in the add-on treatment of schizophrenia
TW202322816A (zh) 2021-08-20 2023-06-16 美商紐羅克里生物科學有限公司 篩選 vmat2 抑制劑之方法
EP4489754A1 (en) * 2022-03-07 2025-01-15 Neurocrine Biosciences, Inc. Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
WO2025038959A1 (en) * 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
TW202521119A (zh) * 2023-08-17 2025-06-01 美商紐羅克里生物科學有限公司 用於投與特定vmat2抑制劑之方法
WO2025188830A1 (en) * 2024-03-06 2025-09-12 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US952A (en) 1838-09-27 I antoni bengini
US10065A (en) 1853-10-04 Improvement in machines for topping cotton jn the field
NZ725826A (en) * 2014-05-06 2023-05-26 Neurocrine Biosciences Inc Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
KR20240125709A (ko) * 2015-06-23 2024-08-19 뉴로크린 바이오사이언시즈 인코퍼레이티드 신경계 질환 또는 장애를 치료하기 위한 vmat2 억제제
CA3051830A1 (en) * 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
MA53239A (fr) * 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2

Also Published As

Publication number Publication date
WO2020227672A1 (en) 2020-11-12
TW202108138A (zh) 2021-03-01
JOP20210274A1 (ar) 2023-01-30
US20200397779A1 (en) 2020-12-24
MA55893A (fr) 2022-03-16
PH12021552745A1 (en) 2022-07-11
AU2025256123A1 (en) 2025-11-13
EA202193012A1 (ru) 2022-03-02
IL321020A (en) 2025-07-01
MX2021013132A (es) 2021-11-25
US20220040169A1 (en) 2022-02-10
CN114340624A (zh) 2022-04-12
JP2025013963A (ja) 2025-01-28
BR112021020709A2 (pt) 2021-12-14
KR20220007105A (ko) 2022-01-18
AU2020270145A1 (en) 2021-12-23
EP3965764A1 (en) 2022-03-16
IL287902A (en) 2022-01-01
SG11202111465RA (en) 2021-11-29
JP2022531696A (ja) 2022-07-08
TWI850377B (zh) 2024-08-01

Similar Documents

Publication Publication Date Title
US10940141B1 (en) Methods for the administration of certain VMAT2 inhibitors
CA3136466A1 (en) Methods for the administration of certain vmat2 inhibitors
US11026931B2 (en) Methods for the administration of certain VMAT2 inhibitors
EP4489754A1 (en) Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
HK40068979A (en) The vmat2 inhibitor valbenazine for use in a method of treating a neurological or psychiatric disorder in patients with severe renal impairment
HK40068979B (en) The vmat2 inhibitor valbenazine for use in a method of treating a neurological or psychiatric disorder in patients with severe renal impairment
WO2025038959A1 (en) Methods for the administration of certain vmat2 inhibitors
WO2025038938A1 (en) Valbenazine for use in the treatment of huntington's chorea

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240506

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250502

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250502

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250507

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250908